A Study to Investigate the Safety, Tolerability and Pharmacokinetics of ABY-035
Status:
Completed
Trial end date:
2018-01-10
Target enrollment:
Participant gender:
Summary
The purpose of this first-in-human study is to investigate the safety and tolerability of
ABY-035 when administered intravenously and subcutaneously, to healthy volunteers and to
psoriasis patients.